| Name | Title | Contact Details |
|---|
Our passion for helping older adults is not something that has developed over night. With 26 years of commitment, our family owned organization has proven to excel in giving loving care to those in need of assistance. It is our mission to provide compassionate care to seniors in a real home environment. We feel that a smaller setting is most ideal for one to receive individual attention and continue establishing meaningful relationships between peers. Our goal is focused on improving the physical and emotional well-being of our residents to help maintain their independence. We are committed to upholding the highest standards of care as we strive to improve quality of life.
Biotics Research Corporation is a Rosenberg, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
For people with life-threatening blood cancers like leukemia and lymphoma or other diseases, a cure exists. Be The Match connects patients with their donor match for a life-saving marrow or umbilical cord blood transplant. Every year, thousands of men, women and children get life-threatening diseases like leukemia and lymphoma. Many of them will die unless they get a bone marrow or cord blood transplant from a genetically matched donor. Some people find a match in their family, but 70% do not. These patients depend on the Be The Match to help them find an unrelated donor or cord blood unit. Whether you want to swab your cheek and join Be The Match Registry, make a financial gift or download a photo to show your support on Facebook, you’re in the right place. The best part? Every action you take helps. Be The Match, operated by National Marrow Donor Program (NMDP), is a nonprofit organization dedicated to creating an opportunity for all patients to receive the marrow or umbilical cord blood transplant they need, when they need it.
Orbus Therapeutics is dedicated to developing products that treat rare diseases for which there are few, if any, effective therapies. The company’s product candidate in development is eflornithine in an oral solution. Eflornithine is a novel cytostatic agent, which Orbus Therapeutics is developing for the treatment of patients with anaplastic glioma (AG), or Grade 3 glioma, a rare form of central nervous system cancer. Eflornithine irreversibly inhibits ornithine decarboxylase (ODC), a key enzyme in mammalian polyamine biosynthesis that is up-regulated in various types of cancer. Orbus Therapeutics intends to develop and commercialize eflornithine in North America.
Repertoire Immune Medicines is working to unleash the remarkable power of the human immune system to prevent, treat or cure cancer, autoimmune conditions, and infectious diseases. Repertoire scientists created and developed a suite of technologies for its DECODE discovery and DEPLOY product platforms that allow in-depth characterization of the immune synapse and the ability to rationally design, and clinically develop, multi-clonal immune medicines. The company is currently conducting experimental medicine clinical trials using autologous T cells primed against cancer antigens and tethered to IL-15.